Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers.
blood–brain barrier
nanocarriers
pediatric brain cancers
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
12 Jan 2022
12 Jan 2022
Historique:
received:
23
11
2021
revised:
04
01
2022
accepted:
07
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Pediatric brain tumors represent the most common types of childhood cancer and novel diagnostic and therapeutic solutions are urgently needed. The gold standard treatment option for brain cancers in children, as in adults, is tumor resection followed by radio- and chemotherapy, but with discouraging therapeutic results. In particular, the last two treatments are often associated to significant neurotoxicity in the developing brain of a child, with resulting disabilities such as cognitive problems, neuroendocrine, and neurosensory dysfunctions/deficits. Nanoparticles have been increasingly and thoroughly investigated as they show great promises as diagnostic tools and vectors for gene/drug therapy for pediatric brain cancer due to their ability to cross the blood-brain barrier. In this review we will discuss the developments of nanoparticle-based strategies as novel precision nanomedicine tools for diagnosis and therapy in pediatric brain cancers, with a particular focus on targeting strategies to overcome the main physiological obstacles that are represented by blood-brain barrier.
Identifiants
pubmed: 35054340
pii: diagnostics12010173
doi: 10.3390/diagnostics12010173
pmc: PMC8774904
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Tecnopolo di Nanotecnologia e Fotonica per la medicina di precisione (TECNO-MED)-FISR/MIUR-CNR
ID : delibera CIPE n.3449 del 7-08-2017
Organisme : Tecnopolo per la medicina di precisione (TecnoMed Puglia)
ID : Regione Puglia: DGR n.2117 del 21/11/2018
Organisme : PON ARS01_00906 TITAN - Nanotecnologie per l'immunoterapia dei tumori
ID : PON "Ricerca e Innovazione" 2014 - 2020 - Azione II - OS 1.b
Organisme : AIRC project under IG 2021
ID : ID. 26328 project
Références
Biomaterials. 2014 Aug;35(26):7588-97
pubmed: 24906346
Neuro Oncol. 2019 Oct 9;21(10):1226-1238
pubmed: 31504801
Nanomedicine. 2014 Jan;10(1):149-57
pubmed: 23891990
Annu Rev Chem Biomol Eng. 2010;1:149-73
pubmed: 22432577
Int J Nanomedicine. 2016 Dec 07;11:6547-6559
pubmed: 27994458
Biomaterials. 2015 Jan;37:425-35
pubmed: 25453970
Eur J Cancer. 2021 May;149:23-33
pubmed: 33819718
Prog Neurobiol. 2019 Oct;181:101665
pubmed: 31376426
Nat Rev Neurol. 2011 Jul 26;7(9):495-506
pubmed: 21788981
Clin Cancer Res. 2006 Nov 15;12(22):6677-86
pubmed: 17121886
PLoS One. 2013 Apr 30;8(4):e62425
pubmed: 23638079
Sci Rep. 2021 Jul 15;11(1):14554
pubmed: 34267303
J Control Release. 2011 Aug 10;153(3):198-205
pubmed: 21663778
Sci Rep. 2018 Jan 19;8(1):1211
pubmed: 29352211
J Drug Target. 2006 May;14(4):191-214
pubmed: 16777679
Exp Neurol. 2004 May;187(1):65-75
pubmed: 15081589
Neurotherapeutics. 2009 Jul;6(3):570-86
pubmed: 19560746
Sci Rep. 2020 Jul 9;10(1):11292
pubmed: 32647151
J Biol Inorg Chem. 2011 Mar;16(3):431-42
pubmed: 21140179
Clin Pharmacol Ther. 2009 May;85(5):531-4
pubmed: 19242401
J Photochem Photobiol B. 2019 Oct;199:111630
pubmed: 31610429
Oncoimmunology. 2016 Nov 18;6(1):e1256527
pubmed: 28197373
Adv Drug Deliv Rev. 2008 May 22;60(8):886-98
pubmed: 18374448
Prog Neurobiol. 2009 Apr;87(4):212-51
pubmed: 19395337
Sci Transl Med. 2013 Oct 30;5(209):209ra152
pubmed: 24174328
Nanomedicine. 2020 Jan;23:102115
pubmed: 31655205
Front Oncol. 2019 May 22;9:423
pubmed: 31192128
Int J Biol Macromol. 2018 Feb;107(Pt A):204-211
pubmed: 28863897
Toxicol Res (Camb). 2016 Sep 13;5(6):1699-1710
pubmed: 30090469
Trends Immunol. 2019 Aug;40(8):748-761
pubmed: 31229353
Adv Colloid Interface Sci. 2015 Jan;215:28-45
pubmed: 25467038
Small. 2011 Aug 22;7(16):2301-6
pubmed: 21630446
Analyst. 2009 Jul;134(7):1373-9
pubmed: 19562204
Int J Pharm. 2018 Sep 5;548(1):540-558
pubmed: 29997043
Paediatr Drugs. 2018 Oct;20(5):395-408
pubmed: 29948928
J Mater Chem B. 2019 Aug 7;7(31):4734-4750
pubmed: 31389961
Int J Mol Sci. 2018 Apr 27;19(5):
pubmed: 29702561
Mol Ther. 2014 Jun;22(6):1075-1083
pubmed: 24599278
J Control Release. 2018 Jan 28;270:290-303
pubmed: 29269142
Nanoscale. 2020 Apr 14;12(14):7927-7938
pubmed: 32232249
Adv Drug Deliv Rev. 2012 May 15;64(7):701-5
pubmed: 22210134
Sci Rep. 2017 Sep 4;7(1):10396
pubmed: 28871203
Cancers (Basel). 2019 Sep 10;11(9):
pubmed: 31510037
Neuroradiology. 2019 May;61(5):535-544
pubmed: 30710184
AAPS J. 2015 Sep;17(5):1041-54
pubmed: 25956384
Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87
pubmed: 16551981
Biomater Sci. 2016 Feb;4(2):219-29
pubmed: 26646694
Chem Rev. 2015 Oct 14;115(19):10637-89
pubmed: 26250431
Small. 2016 Mar 2;12(9):1201-11
pubmed: 26573885
Pharm Res. 2014 Mar;31(3):531-40
pubmed: 23996470
Cancer Res. 2010 Aug 1;70(15):6303-12
pubmed: 20647323
Adv Healthc Mater. 2019 Jan;8(2):e1801359
pubmed: 30549448
J Pharmacol Exp Ther. 2019 Sep;370(3):625-635
pubmed: 30635473
Ital J Pediatr. 2018 Nov 16;44(Suppl 2):131
pubmed: 30442184
ACS Nano. 2019 Apr 23;13(4):3754-3782
pubmed: 30908008
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24205-24212
pubmed: 32934143
Toxicol Sci. 2010 Nov;118(1):160-70
pubmed: 20713472
Nanomedicine (Lond). 2020 Aug;15(18):1805-1815
pubmed: 32698671
Analyst. 2014 Apr 7;139(7):1692-6
pubmed: 24551871
Curr Probl Pediatr Adolesc Health Care. 2012 Apr;42(4):80-103
pubmed: 22433905
Nanotheranostics. 2019 Sep 19;3(4):311-330
pubmed: 31687320
Toxicol Appl Pharmacol. 2003 Oct 1;192(1):1-11
pubmed: 14554098
Pharmaceutics. 2018 Apr 18;10(2):
pubmed: 29670043
J Control Release. 2020 Jul 10;323:463-474
pubmed: 32380205
Bioinorg Chem Appl. 2018 Jul 5;2018:1062562
pubmed: 30073019
Front Chem. 2021 May 24;9:669169
pubmed: 34109155
Front Oncol. 2018 Jul 03;8:239
pubmed: 30018882
Nanomedicine. 2012 Aug;8(6):941-50
pubmed: 22115602
Eur J Pharm Biopharm. 2020 Dec;157:221-232
pubmed: 33130338
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 Jan-Feb;2(1):35-47
pubmed: 20049829
Curr Pharm Des. 2014;20(10):1422-49
pubmed: 23789948
ACS Appl Mater Interfaces. 2016 Nov 30;8(47):32159-32169
pubmed: 27808492
Nanomedicine (Lond). 2016 Apr;11(7):833-49
pubmed: 26980585
Curr Neuropharmacol. 2017;15(1):104-115
pubmed: 26903150
Langmuir. 2008 Jan 15;24(2):568-74
pubmed: 18052300
Drug Deliv. 2004 May-Jun;11(3):169-83
pubmed: 15204636
Mol Pharm. 2013 Jan 7;10(1):249-60
pubmed: 23163881
Radiology. 2014 Nov;273(2 Suppl):S111-25
pubmed: 25340432
Colloids Surf B Biointerfaces. 2016 Sep 1;145:251-256
pubmed: 27187189
Neurol Clin. 2018 Aug;36(3):533-556
pubmed: 30072070
Drug Discov Today. 2008 Dec;13(23-24):1099-106
pubmed: 18848640
Molecules. 2019 Sep 30;24(19):
pubmed: 31574945
Adv Mater. 2018 May 7;:e1705328
pubmed: 29736981
Nano Lett. 2018 Jul 11;18(7):4086-4094
pubmed: 29927251
Lasers Med Sci. 2008 Jul;23(3):217-28
pubmed: 17674122
Curr Neuropharmacol. 2017;15(1):116-128
pubmed: 27306036
Pediatr Res. 2017 Sep;82(3):527-535
pubmed: 28419087
Drug Discov Today. 2018 Feb;23(2):416-423
pubmed: 29074439
J Nanobiotechnology. 2021 Mar 2;19(1):64
pubmed: 33653352
Small. 2014 Dec 29;10(24):5137-50
pubmed: 25104165
Cancer Treat Rev. 2004 Aug;30(5):415-23
pubmed: 15245774
Cancer Lett. 2021 Feb 28;499:220-231
pubmed: 33249196
Nanoscale. 2014 Sep 21;6(18):10865-73
pubmed: 25117686
Biomaterials. 2013 Oct;34(32):7960-70
pubmed: 23880338
Environ Toxicol Pharmacol. 2017 Jul;53:40-45
pubmed: 28501783
Jpn J Pharmacol. 2001 Oct;87(2):97-103
pubmed: 11700018
Mol Oncol. 2015 Jun;9(6):1071-80
pubmed: 25681012
Nanoscale. 2016 Sep 22;8(37):16662-16669
pubmed: 27714111